Pliant Therapeutics, Inc. Appoints Gayle Crowell to Its Board of Directors
January 08, 2020 at 08:00 am EST
Share
Pliant Therapeutics, Inc. announced the appointment of Gayle Crowell to its board of directors as an independent director. Ms. Crowell will serve on the both the audit committee and nominating and governance committee. Ms. Crowell has a long-standing track record of leadership and management in the technology industry, with particular experience in operations and organizational development. She spent the past decade as a strategic business advisor for Warburg Pincus, one of the world's leading private equity firms, where she worked closely with leading high growth companies to help drive commercial business strategy, accelerate revenue growth, evaluate market opportunities and build world-class management teams. A veteran board member, having served on over 20 public and private company boards, she is currently also serving on the Boards of Envestnet (ENV) and Hercules Capital (HTGC). In addition, Ms. Crowell serves as a trustee of the prestigious Desert Research Foundation and has served as chairman and on the National Board of Directors for Watermark, a non-profit women's executive organization. A long-time ecologist and educator, she is also the co-founder of Conserving Now, a large community of active environmentalists.
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvÃ6 and αvÃ1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvÃ1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvÃ8 and αvÃ1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.